Fig. 1From: Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trialReductions in MMD from baseline in the 3 top-recruiting countries and all other countries during a) 12 weeks and at b) 4 weeks. MMD monthly migraine days. aP < 0.01 versus placebo. bP < 0.001 versus placebo. P < 0.05 versus placeboBack to article page